Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

ClinicalTrials.gov ID: NCT00827112

Public ClinicalTrials.gov record NCT00827112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naïve HIV-Infected Patients With R5 HIV-1

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.

Study identification

NCT ID
NCT00827112
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ViiV Healthcare
Industry
Enrollment
129 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2009
Primary completion
Jun 30, 2010
Completion
Jun 30, 2011
Last update posted
Jun 14, 2012

2009 – 2011

United States locations

U.S. sites
27
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
Pfizer Investigational Site Los Angeles California 90027
Pfizer Investigational Site Los Angeles California 90028
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Los Angeles California 90069
Pfizer Investigational Site Norwalk Connecticut 06851
Pfizer Investigational Site Washington D.C. District of Columbia 20009
Pfizer Investigational Site Miami Florida 33133
Pfizer Investigational Site Miami Florida 33136
Pfizer Investigational Site Miami Florida 33137
Pfizer Investigational Site Orlando Florida 32803
Pfizer Investigational Site Pensacola Florida 32504
Pfizer Investigational Site St. Petersburg Florida 33713
Pfizer Investigational Site Tampa Florida 33602
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site Atlanta Georgia 30312
Pfizer Investigational Site Chicago Illinois 60657
Pfizer Investigational Site Springfield Massachusetts 01107
Pfizer Investigational Site Springfield Massachusetts 01199
Pfizer Investigational Site Ann Arbor Michigan 48109
Pfizer Investigational Site Omaha Nebraska 68106
Pfizer Investigational Site New York New York 10003
Pfizer Investigational Site Huntersville North Carolina 28078
Pfizer Investigational Site Addison Texas 75001
Pfizer Investigational Site Dallas Texas 75204
Pfizer Investigational Site Dallas Texas 75390
Pfizer Investigational Site Houston Texas 77098
Pfizer Investigational Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00827112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 14, 2012 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00827112 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →